Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers

F. Grossi, M. Loprevite, M. Chiaramondia, P. Ceppa, C. Pera, G. B. Ratto, J. Serrano, G. B. Ferrara, R. Costa, L. Boni, A. Ardizzoni

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.

Original languageEnglish
Pages (from-to)1242-1250
Number of pages9
JournalEuropean Journal of Cancer
Volume39
Issue number9
DOIs
Publication statusPublished - Jun 2003

Fingerprint

Proliferating Cell Nuclear Antigen
Non-Small Cell Lung Carcinoma
Mutation
Survival
Squamous Cell Carcinoma
Multivariate Analysis
Kaplan-Meier Estimate
Biological Factors
Proportional Hazards Models
Codon
Exons
Nucleotides
Immunohistochemistry
Polymerase Chain Reaction
Neoplasms
Proteins

Keywords

  • bcl-2
  • Biologic markers
  • CD34
  • K-ras
  • Lung cancer
  • p53
  • PCNA
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. / Grossi, F.; Loprevite, M.; Chiaramondia, M.; Ceppa, P.; Pera, C.; Ratto, G. B.; Serrano, J.; Ferrara, G. B.; Costa, R.; Boni, L.; Ardizzoni, A.

In: European Journal of Cancer, Vol. 39, No. 9, 06.2003, p. 1242-1250.

Research output: Contribution to journalArticle

Grossi, F, Loprevite, M, Chiaramondia, M, Ceppa, P, Pera, C, Ratto, GB, Serrano, J, Ferrara, GB, Costa, R, Boni, L & Ardizzoni, A 2003, 'Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers', European Journal of Cancer, vol. 39, no. 9, pp. 1242-1250. https://doi.org/10.1016/S0959-8049(03)00232-6
Grossi, F. ; Loprevite, M. ; Chiaramondia, M. ; Ceppa, P. ; Pera, C. ; Ratto, G. B. ; Serrano, J. ; Ferrara, G. B. ; Costa, R. ; Boni, L. ; Ardizzoni, A. / Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. In: European Journal of Cancer. 2003 ; Vol. 39, No. 9. pp. 1242-1250.
@article{0e494cf270674111918e64d3282e90e0,
title = "Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers",
abstract = "The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.",
keywords = "bcl-2, Biologic markers, CD34, K-ras, Lung cancer, p53, PCNA, Prognostic factors",
author = "F. Grossi and M. Loprevite and M. Chiaramondia and P. Ceppa and C. Pera and Ratto, {G. B.} and J. Serrano and Ferrara, {G. B.} and R. Costa and L. Boni and A. Ardizzoni",
year = "2003",
month = "6",
doi = "10.1016/S0959-8049(03)00232-6",
language = "English",
volume = "39",
pages = "1242--1250",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers

AU - Grossi, F.

AU - Loprevite, M.

AU - Chiaramondia, M.

AU - Ceppa, P.

AU - Pera, C.

AU - Ratto, G. B.

AU - Serrano, J.

AU - Ferrara, G. B.

AU - Costa, R.

AU - Boni, L.

AU - Ardizzoni, A.

PY - 2003/6

Y1 - 2003/6

N2 - The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.

AB - The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.

KW - bcl-2

KW - Biologic markers

KW - CD34

KW - K-ras

KW - Lung cancer

KW - p53

KW - PCNA

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0038579659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038579659&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(03)00232-6

DO - 10.1016/S0959-8049(03)00232-6

M3 - Article

C2 - 12763212

AN - SCOPUS:0038579659

VL - 39

SP - 1242

EP - 1250

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -